Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemtabrutinib Pharmacokinetics in Severe Renal Impairment
NCT07734610Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of nemtabrutinib, sponsored by Merck & Co. Primary endpoint: Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity of Nemtabrutinib in Plasma at 336 hours. Started Sep 2026; status: recruiting.
02
Drugs
nemtabrutinib
Beyond the preview
Go deeper on NCT07734610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07734610.